Pharmidex will be attending “The 17th Annual BIO CEO & Investor Conference”

February 9, 2015

The BIO CConference is one of the largest investor conference focused on established and emerging publicly traded and select private biotech companies.

Pharmidex will be attending “The 17th Annual BIO CEO & Investor Conference”

The BIO CEO & Investor Conference is one of the largest investor conference focused on established and emerging publicly traded and select private biotech companies.

Those attending the conference will have the opportunity to explore a broad variety of industry related investment opportunities. Additionally delegates would have a chance to network with institutional investors, industry analysts & senior biotechnology executives.

Because our mission is to support industry-wide success, we present a broad and unbiased view of investment opportunities. BIO One-on-One Partnering provides an opportunity to arrange meetings between investors; companies; and industry BD, licensing and therapeutic franchise heads.

The event will be taking place on the 9-10 February 2015, New York City, NY, USA.

< Older Post

Newer Post >

🌟 Pharmidex is proud to sponsor CamMedChem’25! 🌟

September 12, 2025

We’re delighted to announce that Pharmidex will be an official sponsor of CamMedChem’25 , the renowned meeting organized by the Royal Society of Chemistry’s Biomolecular Chemistry Special Interest Group This year’s theme promises cutting-edge discussions in medicinal chemistry, biomolecular interactions and the latest trends in small molecule and chemical biology research. We’re honoured to support such a pivotal forum for scientists, drug discovery experts and academic innovators to exchange ideas, foster collaborations, and advance therapeutic discovery. 👉 We look forward to: Learning from the powerful scientific insights shared at the meeting Exploring new partnerships that further the translation of biomolecular science into impactful therapies We can’t wait to see you in Cambridge for CamMedChem’25!

Pharmidex Histology Services: Precision You Can Trust

September 8, 2025

At Pharmidex , we deliver comprehensive histology solutions designed to support preclinical and clinical research with accuracy and reliability. 🔬 From sample to slide, our services include: tissue processing, embedding, microtomy, routine and special staining, digital imaging and slide scanning all underpinned by rigorous quality control and expert scientific oversight. With specialist capabilities and high-throughput workflows, we help researchers generate high-quality, reproducible data across toxicology, oncology, CNS and beyond. 👉 Learn more: pharmidex.com/histology

🔬 Expanding our integrated capabilities in autoimmune research

September 3, 2025

At Pharmidex , we are proud to offer a comprehensive preclinical platform for autoimmune disease research. Using in vivo EAE models, we combine: ✔️ Bioanalysis & biomarker profiling to quantify key cytokines and mediators of disease progression ✔️ Histological assessment, enabling detailed evaluation of inflammation, demyelination and tissue pathology across multiple organs ✔️ Pharmacological intervention studies, including established treatments This integrated approach delivers a complete and translationally relevant dataset, supporting drug discovery and development programmes from mechanistic insight through to therapeutic evaluation. By combining in vivo efficacy, biomarker analysis and histology, our team provides partners with a more comprehensive understanding of disease mechanisms and treatment effects. 👉 Learn more about our services in Histology, Biomarker Analysis, and Autoimmune Disease Models.